Norges Bank Adc Therapeutics Sa Transaction History

Norges Bank

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 07, 2021	SELL	$22.75 - $34.05 $1.37 Million - $2.04 Million	-60,000 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$25.26 - $38.02 $1.52 Million - $2.28 Million	60,000 New	60,000 $1.92 Million
Q4 2020 Feb 10, 2021	SELL	$25.26 - $38.02 $1.52 Million - $2.28 Million	-60,000 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$32.87 - $51.05 $1.97 Million - $3.06 Million	60,000 New	60,000 $1.98 Million
Q3 2020 Nov 10, 2020	SELL	$32.87 - $51.05 $328,700 - $510,500	-10,000 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$29.65 - $46.81 $296,500 - $468,100	10,000 New	10,000 $468,000

55.1M

82.7K

31.5K

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $175M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.